<DOC>
	<DOCNO>NCT03095040</DOCNO>
	<brief_summary>This randomize , double blind , phase 2/3 study aim evaluate efficacy safety CM082 combination everolimus Chinese patient advance renal cell carcinoma . The primary endpoint progression-free survival .</brief_summary>
	<brief_title>CM082 Combined With Everolimus Chinese Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis clear cell renal cell carcinoma Progressed least one standard therapy VEGFR TKI Measurable disease per Recist v1.1 Eastern Cooperative Group ( ECOG ) Performance Status score 0 1 Life expectancy least 12 week Adequate organ function , meet following requirement : Bone marrow : ANC ≥1.5*109/L ( 1500/mm3 ) , platelet ≥100*109/L , hemoglobin ≥9 g/dL Liver : Total bilirubin ≤1.5 time upper limit normal ( ULN ) ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤1.5x upper limit normal ( ULN ) liver involvement ≤5x upper limit normal liver involvement Kidney : Creatinine ≤ 1.25 x ULN , urine protein &lt; 1+ Heart : LVEF ≥ 50 % Willingness ability comply trial followup procedure Ability understand nature trial give write informed consent Currently receive anticancer treatment ; currently previously receive 2 systemic anticancer treatment Other tumor addition renal cell carcinoma Females pregnant breastfeed Known hypersensitivity CM082 everolimus Those concurrent condition ( e.g . psychological , neuronal , cardiovascular , respiratory condition infection ) investigator 's opinion would jeopardize compliance protocol Patients known central nervous system ( CNS ) metastases Presence active gastrointestinal ( GI ) disease condition interfere significantly absorption , distribution , metabolism , excretion CM082 everolimus Any active infection Drug alcohol abuser</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>